| Chronic Obstructive Pulmonary Disease |
1 |
1 |
| Eosinophils |
0 |
0.97 |
| Corticosteroids |
0 |
0.98 |
| Steroids |
0 |
0.35 |
| Primary Care |
0 |
0.3 |
| Biomarker |
0 |
0.99 |
| UK Site Content |
0 |
0.2 |
| NHS |
0 |
0.16 |
| Antibiotics |
0 |
0.15 |
| Blood |
0 |
0.15 |
| Point-of-Care |
0 |
0.15 |
| Clinical Guidelines |
0 |
0.14 |
| Grant |
0 |
0.1 |
| Thromboembolism |
0 |
0.09 |
| Adverse Effects |
0 |
0.05 |
| Asthma |
0 |
0.05 |
| Chemotherapy |
0 |
0.05 |
| Europe |
0 |
0.05 |
| Fractures |
0 |
0.05 |
| Health Care Economics |
0 |
0.05 |
| Investment |
0 |
0.05 |
| Lung |
0 |
0.05 |
| Match |
0 |
0.05 |
| Moderate COPD |
0 |
0.05 |
| Patient Safety |
0 |
0.05 |
| Sepsis |
0 |
0.05 |
| Social Determinants of Health |
0 |
0.05 |
| Venous Thromboembolism (VTE) |
0 |
0.05 |